{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-048248","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.431810+00:00","generated_at":"2026-05-17T00:51:12.149776+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Castle Biosciences Q3 revenue $83M, raises FY2025 guidance to $327-335M; launches AdvanceAD-Tx test","bullets":["Revenue $83.0M (Q3 2025) vs $85.8M YoY; net loss $0.5M vs net income $2.3M.","Total test reports 26,841; DecisionDx-Melanoma and TissueCypher each exceeded 10,000 tests in a quarter for first time.","Full-year 2025 revenue guidance raised to $327-335M from $310-320M.","Launched AdvanceAD-Tx, a GEP test to guide systemic treatment for moderate-to-severe atopic dermatitis.","Non-dermatologic revenue up 67% YoY; adjusted EBITDA $9.2M vs $21.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-048248","json":"https://secwatch.observer/filing/0001628280-25-048248.json","markdown":"https://secwatch.observer/filing/0001628280-25-048248.md","text":"https://secwatch.observer/filing/0001628280-25-048248.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000162828025048248/0001628280-25-048248-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000162828025048248/cstl-20251103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:51:12.149776+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}